Drug Insights

Is Casimersen approved by the FDA?

10 July 2024
3 min read

Casimersen, marketed under the brand name Amondys 45, is a medication designed to treat Duchenne muscular dystrophy (DMD) in patients with a specific gene mutation. Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021. The approval was granted on an accelerated basis, which means that while initial studies showed positive responses, further clinical trials are required to confirm its long-term benefits.

Uses and Administration

Uses:

  • Casimersen is used to treat Duchenne muscular dystrophy in individuals who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This genetic specificity is crucial for the drug's effectiveness.

Administration:

  • The medication is administered as an intravenous (IV) infusion, usually once a week.
  • The infusion process is slow, typically taking between 35 to 60 minutes.
  • Dosage is based on the patient's weight, with regular adjustments as weight fluctuates.

Precautions and Considerations

Before Taking Casimersen:

  • Patients should inform their healthcare provider about any known kidney problems, as well as any other medical conditions or allergies.
  • It is important to discuss with the doctor if the patient is pregnant or breastfeeding.

Potential Side Effects:

  • Serious Side Effects: Pink, brown, or red urine; foamy urine; swelling in the face, hands, feet, or stomach.
  • Common Side Effects: Headache, fever, joint pain, cough, cold symptoms (stuffy nose, sneezing, sore throat).

Patients should report any side effects to their healthcare provider or directly to the FDA at 1-800-FDA-1088.

Detailed Dosage Information

Usual Adult and Pediatric Dose for Muscular Dystrophy:

  • 30 mg/kg via IV infusion once a week.
  • Approval was based on the increase in dystrophin production in skeletal muscle observed in clinical trials.

Missed Dose:

  • If a dose is missed, patients should contact their doctor for instructions. Maintaining a regular infusion schedule is crucial for the effectiveness of the treatment.

Conclusion

This medication provides a targeted treatment option for patients with Duchenne muscular dystrophy who have a specific genetic mutation. As with any treatment, it is important for patients to discuss their medical history and potential risks with their healthcare provider to ensure safe and effective use. Continued research and clinical trials will further elucidate the long-term benefits and effectiveness of casimersen.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

European Union Approval for Mirum Pharmaceuticals’ LIVMARLI to Treat PFIC Patients
Latest Hotspot
3 min read
European Union Approval for Mirum Pharmaceuticals’ LIVMARLI to Treat PFIC Patients
10 July 2024
Mirum Pharmaceuticals, Inc. revealed that the European Commission has approved the marketing authorization for LIVMARLI® (maralixibat) oral solution
Read →
Is Trilaciclib approved by the FDA?
Drug Insights
3 min read
Is Trilaciclib approved by the FDA?
10 July 2024
Trilaciclib was approved by the U.S. Food and Drug Administration (FDA) on February 12, 2021.
Read →
The European Union has approved Dupixent® (dupilumab) as the first targeted therapy for COPD patients
Latest Hotspot
4 min read
The European Union has approved Dupixent® (dupilumab) as the first targeted therapy for COPD patients
10 July 2024
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.
Read →
Is Evinacumab approved by the FDA?
Drug Insights
3 min read
Is Evinacumab approved by the FDA?
10 July 2024
Evinacumab was approved by the U.S. Food and Drug Administration (FDA) on February 11, 2021.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.